Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

FMX 8

Next Previous
Drug Profile

FMX 8

Alternative Names: FMX-8

Latest Information Update: 13 May 2017

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator FerruMax Pharmaceuticals
  • Class Antianaemics; Recombinant fusion proteins
  • Mechanism of Action Hepcidin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Anaemia

Most Recent Events

  • 12 May 2017 Discontinued - Phase-II for Anaemia in USA (IV), because no recent reports on development were identified further to phase II trial termination
  • 17 Jul 2014 FerruMax Pharmaceuticals plans a phase 0 trial in Anaemia in USA (NCT02228655)
  • 25 Mar 2014 FerruMax Pharmaceuticals terminates a phase IIa trial in Anaemia in USA (NCT01873534)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top